Matinas Biopharma Holdings, Inc. (MTNB): Price and Financial Metrics

Matinas Biopharma Holdings, Inc. (MTNB): $0.21

0.01 (+4.90%)

POWR Rating

Component Grades








Add MTNB to Watchlist
Sign Up

Industry: Biotech




#116 of 361

in industry

MTNB Price/Volume Stats

Current price $0.21 52-week high $0.89
Prev. close $0.20 52-week low $0.11
Day low $0.20 Volume 816,244
Day high $0.21 Avg. volume 2,900,793
50-day MA $0.21 Dividend yield N/A
200-day MA $0.34 Market Cap 45.60M

MTNB Stock Price Chart Interactive Chart >

MTNB Stock Summary

  • MTNB's price/sales ratio is 10.8; that's higher than the P/S ratio of 91.49% of US stocks.
  • As for revenue growth, note that MTNB's revenue has grown 34.38% over the past 12 months; that beats the revenue growth of 85.94% of US companies in our set.
  • The volatility of MATINAS BIOPHARMA HOLDINGS INC's share price is greater than that of 91.13% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to MTNB, based on their financial statements, market capitalization, and price volatility, are ADVM, HLTH, SPRO, BPMC, and DCPH.
  • Visit MTNB's SEC page to see the company's official filings. To visit the company's web site, go to

MTNB Valuation Summary

  • MTNB's price/sales ratio is 11.7; this is 588.24% higher than that of the median Healthcare stock.
  • MTNB's price/sales ratio has moved NA NA over the prior 81 months.

Below are key valuation metrics over time for MTNB.

Stock Date P/S P/B P/E EV/EBIT
MTNB 2023-11-03 11.7 1.8 -2.4 -2.1
MTNB 2023-11-02 10.8 1.7 -2.2 -1.9
MTNB 2023-11-01 10.6 1.6 -2.2 -1.9
MTNB 2023-10-31 11.1 1.7 -2.3 -2.0
MTNB 2023-10-30 10.6 1.6 -2.2 -1.9
MTNB 2023-10-27 10.9 1.7 -2.3 -2.0

MTNB Growth Metrics

    Its 2 year price growth rate is now at -16.1%.
  • Its year over year net income to common stockholders growth rate is now at -5.6%.
  • The 4 year cash and equivalents growth rate now stands at -36.04%.
MTNB's revenue has moved down $0 over the prior 30 months.

The table below shows MTNB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0 -18.81434 -24.06189
2022-06-30 0 -19.5956 -25.43685
2022-03-31 0 -15.32802 -24.49027
2021-12-31 0 -15.22345 -23.67921
2021-12-31 0 -15.22345 -23.67921
2021-09-30 0 -15.57345 -23.5387

MTNB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MTNB has a Quality Grade of C, ranking ahead of 46.5% of graded US stocks.
  • MTNB's asset turnover comes in at 0 -- ranking 440th of 682 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with MTNB.

The table below shows MTNB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -0.407
2021-03-31 0 NA -0.376
2020-12-31 0 NA -0.342
2020-09-30 0 NA -0.388
2020-06-30 0 NA -0.490
2020-03-31 0 NA -0.639

Matinas Biopharma Holdings, Inc. (MTNB) Company Bio

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections.

MTNB Latest News Stream

Event/Time News Detail
Loading, please wait...

MTNB Latest Social Stream

Loading social stream, please wait...

View Full MTNB Social Stream

Latest MTNB News From Around the Web

Below are the latest news stories about MATINAS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate MTNB as an investment opportunity.

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript November 8, 2023 Matinas BioPharma Holdings, Inc. reports earnings inline with expectations. Reported EPS is $-0.03 EPS, expectations were $-0.03. Operator: Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, […]

Yahoo | November 10, 2023

12 Best Day Trading Stocks To Buy

In this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy. Over the past few years, the rise of a new generation of stock traders that like to engage in risky bets, […]

Yahoo | November 9, 2023

Q3 2023 Matinas BioPharma Holdings Inc Earnings Call

Q3 2023 Matinas BioPharma Holdings Inc Earnings Call

Yahoo | November 9, 2023

Matinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progress

Key Developments and Financial Highlights for Investors

Yahoo | November 8, 2023

Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

FDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint under evaluation to strengthen commercial opportunity without increasing study size Patient with Candida krusei infection achieved complete clinical resolution with MAT2203; additional patient enrolled in the Compassionate/Expanded Use Access Program Oral LNC formulation of docetaxel showed reductio

Yahoo | November 8, 2023

Read More 'MTNB' Stories Here

MTNB Price Returns

1-mo -4.28%
3-mo 21.60%
6-mo -47.30%
1-year -68.18%
3-year -80.37%
5-year -75.00%
YTD -58.00%
2022 -50.50%
2021 -25.74%
2020 -40.09%
2019 281.51%
2018 -48.71%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!